Discovery and Structure Enabled Synthesis of 2,6-Diaminopyrimidin-4-one IRAK4 Inhibitors.Seganish, W.M., Fischmann, T.O., Sherborne, B., Matasi, J., Lavey, B., McElroy, W.T., Tulshian, D., Tata, J., Sondey, C., Garlisi, C.G., Devito, K., Fossetta, J., Lundell, D., Niu, X.
(2015) ACS Med Chem Lett 6: 942-947
- PubMed: 26288698
- DOI: https://doi.org/10.1021/acsmedchemlett.5b00279
- Primary Citation of Related Structures:
4ZTL, 4ZTM, 4ZTN
- PubMed Abstract:
We report the identification and synthesis of a series of aminopyrimidin-4-one IRAK4 inhibitors. Through high throughput screening, an aminopyrimidine hit was identified and modified via structure enabled design to generate a new, potent, and kinase selective pyrimidin-4-one chemotype. This chemotype is exemplified by compound 16, which has potent IRAK4 inhibition activity (IC50 = 27 nM) and excellent kinase selectivity (>100-fold against 99% of 111 tested kinases), and compound 31, which displays potent IRAK4 activity (IC50 = 93 nM) and good rat bioavailability (F = 42%).
Discovery Chemistry, Structural Sciences, Computational Chemistry, In Vitro Pharmacology, and Respiratory and Immunology, Merck Research Laboratories , 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States.